Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Lyman on Bringing Biosimilars From Bench to Bedside in Oncology

November 2nd 2020

In our exclusive interview, Gary H. Lyman, MD, MPH, discusses the current state of biosimilars in oncology, the pathways that have been established to ensure the safe delivery of these agents to patients, and the potential effects they could have on alleviating some of the current constraints within the health care system.

Raez on the Rise of Liquid Biopsy in Lung Cancer

October 29th 2020

In our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.

FDA Approval Insights: Selinexor in Relapsed/Refractory DLBCL

October 26th 2020

In our exclusive interview, Brian T. Hill, MD, PhD, provides perspective on the FDA approval of selinexor in relapsed/refractory diffuse large B-cell lymphoma.

FDA Approval Insights: Daratumumab / Carfilzomib / Dexamethasone in Myeloma

October 22nd 2020

In our exclusive interview, Saad Z. Usmani, MD, FACP, discusses the FDA approval of daratumumab, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma.

Gandara Evaluates Opportunities for Virtual Education, Expansion, and Engagement Amid COVID-19

October 19th 2020

In our exclusive interview, David R. Gandara, MD highlights the benefits and challenges of delivering patient care virtually and its reception among patients, discusses the sustainability of virtual CME platforms and forecasts what the “new normal” of oncology education may look like as a result of the pandemic.

Garcia-Manero Previews Potential Therapeutic Standards in TP53-Mutated MDS/AML

October 15th 2020

In our exclusive interview, Guillermo Garcia-Manero, MD, discusses the prevalence of TP53 mutations in myelodysplastic syndromes and acute myeloid leukemia, the prognosis these mutations confer, and the development of eprenetapopt and magrolimab in this patient population.

Gutierrez Provides Insight on Bridging Gaps in Cancer Care

October 12th 2020

In our exclusive interview, Rodolfo Gutierrez, MD, discusses the issues that surround access to care and clinical outcomes with Hispanic patients, efforts The Angeles Clinic has spearheaded to bridge this gap in care, and the importance of patient and provider education and awareness.

Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors

October 8th 2020

In our exclusive interview, Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in tumor mutational burden–high solid tumors, shares the “transformative importance” of the regulatory decision, and speaks to the controversy surrounding the approval.

O’Regan on Protocols, Best Practices, and Virtual Etiquette for Cancer Care in Light of COVID-19

October 5th 2020

In our exclusive interview, O’Regan discusses the protocols the University of Wisconsin Carbone Cancer Center has put into place in light of COVID-19, the rise of telemedicine, best practices for in-person visits in the clinic, and the importance of maintaining well visits throughout the pandemic.

FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

October 1st 2020

In our exclusive interview, Dr. Leonard discusses the FDA approval of tazemetostat in patients with relapsed/refractory follicular lymphoma whose tumors are EZH2 positive, as well as those with relapsed/refractory follicular lymphoma who have no other available satisfactory treatment options, and the benefits of providing another agent for this subset of patients.

FDA Approval Insights: Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer

September 28th 2020

In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.

FDA Approval Insights: Lurbinectedin in Metastatic SCLC

September 24th 2020

In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.

Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer

September 21st 2020

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma

September 17th 2020

In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.

Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer

September 14th 2020

In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.

Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer

September 10th 2020

In our exclusive interview, Sara M. Tolaney, MD, MPH, shares insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.

Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer

September 7th 2020

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer

September 3rd 2020

In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.

GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer

August 31st 2020

Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.

FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma

August 27th 2020

In our exclusive interview, Shilpa Gupta, MD, of Cleveland Clinic, discusses the FDA approval of avelumab in metastatic urothelial carcinoma and key findings from the JAVELIN Bladder 100 study.